Key Highlights

  • ARGX shares rose 3.17% in Wednesday's session to $1,051.76, up from a prior close of $1,019.49.
  • The stock is rebounding sharply after Monday's profit-taking dip, nearing its 52 week high of $1,058.69.
  • UBS upgraded the stock to Buy from Neutral and raised its price target to $1,400 from $960.
  • Wells Fargo raised its price target to $1,415 from $1,350 while maintaining an Overweight rating.
  • Trading Volume reached approximately 233,230 shares.

Analyst Upgrades Reinforce Confidence After Phase 3 Data

argenx SE (NASDAQ:ARGX), a global immunology company headquartered in Amsterdam, saw its shares climb toward 52 week highs following a wave of bullish analyst commentary. The advance follows the company's positive Phase 3 ALKIVIA topline results in autoimmune myositis, announced August 17.

UBS upgraded argenx to Buy from Neutral and raised its price target to $1,400 from $960, while Wells Fargo raised its target to $1,415 from $1,350 and maintained an Overweight rating. Both firms cited a strengthened outlook for the company's efgartigimod pipeline following the ALKIVIA data.

The stock's advance also tracks a broader rotation into healthcare and biotech names, with the sector benefiting from renewed mergers-and-acquisitions activity and improving investor sentiment. argenx shares had pulled back on Monday amid broader profit-taking before rebounding sharply through the week.

Pipeline Breadth and Tender Offer Add to the Narrative

argenx's flagship Franchise is built on efgartigimod, marketed as VYVGART and VYVGART Hytrulo, which is approved for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The company is pursuing additional indications for the drug, including immune thrombocytopenia, pemphigus vulgaris, and thyroid eye disease.

The company carries a market Capitalization of approximately $65.41 billion, with trailing Earnings Per Share of $11.08. argenx is separately working through a tender offer to acquire Forte Biosciences for $77.00 per share, a transaction that would add to its broader portfolio of novel candidates, including empasiprubart, ARGX-119, ARGX-213, and cusatuzumab.

The company's SIMPLE Antibody and NHANCE discovery platforms underpin its pipeline expansion, and argenx maintains collaborations with partners including AbbVie, Genmab, Zai Lab, and LEO Pharma.

Momentum Builds Ahead of Additional Catalysts

argenx's rebound reflects both the strength of its recent clinical data and a broader wave of analyst confidence in its expanding efgartigimod franchise. Investors are likely to watch the progress of the Forte Biosciences tender offer alongside additional pipeline readouts as the next catalysts for the stock.